Biotechnology
The First US World-Class Bioscience Design Corporation Officially Launched
TAIPEI, Sept. 22, 2021 /PRNewswire/ -- TCI Co., Ltd. set up a subsidiary in the United States for the first time in 2019 to expand its business footprint and bring its successful experience inAsia to the United States. After two years of continuous effort, it has accumulated a series of extensiv...
2021-09-23 09:00
680
Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
* Trial enrolled over 30,000 adult & elderly participants across 4 continents; 100% of SARS-CoV-2 strains observed in efficacy analysis were variants (Delta was predominant strain) * Primary and secondary efficacy endpoints were successfully met * 100% efficacy against severe COVID-19 & hosp...
2021-09-22 18:56
605
Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA
INCHEON, South Korea, Sept. 22, 2021 /PRNewswire/ -- Samsung Biologics, a global contract development and manufacturing organization (CDMO), introduced its proprietary technology platform, S-CellerateTM, at the BioProcess International Conference (BPI 2021) to offer clients an integrated and seam...
2021-09-22 18:00
496
Asieris Appoints Dr. Alice Chen as Vice President, Discovery Biology and Head of Translational Research
SHANGHAI, Sept. 22, 2021 /PRNewswire/ -- Asieris Pharmaceuticals announced the appointment of Dr.Alice Chen as Vice President, Discovery Biology and Head of Translational Research with effect fromSeptember 20, 2021. She will report to Dr.Kevin Pan, Founder and CEO of Asieris. Alice has over 20 ...
2021-09-22 14:45
520
New Therapy to Treat Advanced Small Cell Lung Cancer ZEPZELCA® (lurbinectedin) Approved in Singapore
Highlights: * ZEPZELCA® (lurbinectedin) is the first new therapy approved in Singapore to treat 2L metastatic small cell lung cancer (SCLC) in 20 years * ZEPZELCA provisional approval represents an important advance for adult patients whose metastatic SCLC has progressed on or after platinum-...
2021-09-22 14:30
570
Origin Agritech and China Agricultural University to Collaborate on Research of Molecular Design of Corn Using CRISPR
BEIJING, Sept. 21, 2021 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), an agriculture technology company, today announced that it has entered into collaboration agreement with China Agricultural University for the research of molecular design in corn. One of the...
2021-09-21 21:36
3686
Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021
MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that data was present...
2021-09-20 22:51
5899
PharmAbcine to Participate in BIO-Europe 2021
DAEJEON, South Korea, Sept. 20, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will virtually participate in the 27th annual BIO-Europe which will tak...
2021-09-20 20:00
611
Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial
* Rapid oral absorption of BNC210 novel tablet formulation potentially well-suited for acute treatment of anxiety in patients with Social Anxiety Disorder * Phase 2 clinical trial on target to start by end of 2021 and expected to read out topline data by end of 2022 ADELAIDE, Australia, Sept....
2021-09-20 18:00
2677
Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO
SHANGHAI, Sept. 19, 2021 /PRNewswire/ -- On September 19, 2021, CARsgen Therapeutics (stock code: 2171.HK) disclosed the latest progress of the investigator-initiated trial (IIT) of Claudin18.2 (CLDN18.2) CAR-T (CT041) for the treatment of digestive system tumors. Results of this trial have been ...
2021-09-20 08:24
3463
2021 CSCO | Henlius will Release Four Oral Presentations of Two Upcoming Commercial Products: Novel anti-PD-1 mAb Serplulimab and Bevacizumab Biosimilar
SHANGHAI, Sept. 18, 2021 /PRNewswire/ -- The 24th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) will be held online and in-person from 25th to 29th September 2021. In this meeting, Henlius will release 4 study results of 2 products to be commercialized, the novel anti-PD-1 mAb ser...
2021-09-18 20:00
10609
The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for First-Line Treatment of sqNSCLC Accepted by China's NMPA, Phase 3 MRCT Met its Primary Endpoint
SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of Serplulimab Injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb) independently developed by the company, in combination with carboplatin and albumin-bound ...
2021-09-17 20:00
3308
Zhongchao Inc. Launches Hematology MDT Training Platform to Improve Diagnosis and Treatment
SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patients the patient management p...
2021-09-17 18:30
789
Arctic Vision Announces Addition of Novel Mydriatic Drug MydCombi™ (ARVN004) to Eyenovia Commercialization Deal
SHANGHAI, Sept. 16, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today that it will expand its exclusive license agreement with Eyenovia, Inc. (NASDAQ: EYEN) to include a third asset, MydCombi™, for development and commerc...
2021-09-17 08:00
753
Bridge Biotherapeutics Presents Pre-Clinical Data of BBT-176 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
* Pre-clinical data exploring the in vitro and in vivo efficacy of BBT-176 will be disclosed via an ePoster at the ESMO Congress 2021 * Patient dosing for the phase 1/2 clinical study of BBT-176 was initiated in April 2021…the topline data of the first-in-human, dose escalation study is expec...
2021-09-17 06:00
761
COVID-19 Scoop: Epoch-Making GoldenBiotech's Oral COVID-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe COVID-19 Patients
TAIPEI, Sept.16, 2021 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132) ("GoldenBiotech", GBC), a leading Taiwanese biopharmaceutical company, announces that its oral investigational new drug Antroquinonol (HOCENA®) has made headway withCOVID-19 treatment development in more broaden clinical ...
2021-09-16 18:05
1100
Laekna Therapeutics reported positive results in two clinical studies for the treatment of various stages of prostate cancer at the ESMO Congress
SHANGHAI and WARREN, New Jersey, Sept. 16, 2021 /PRNewswire/ -- Laekna Therapeutics, an emerging innovative biotech company based inChina's "Zhangjiang Pharma Valley" andNew Jersey, USA, focusing on the development of ground-breaking innovative therapies to treat cancer and liver diseases, repor...
2021-09-16 17:06
559
GeneQuantum announces two key leadership appointments
SUZHOU, China, Sept. 15, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry-leading biotech company dedicated to the next generation bioconjugate drugs based on the innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announced the appointment of Dr.Li Wan as the ...
2021-09-16 09:00
684
Prenetics, a Global Leader in Genomic and Diagnostic Testing, to Become Publicly Traded on the Nasdaq via Merger with Adrian Cheng's Artisan Acquisition Corp.
* Prenetics' mission is to disrupt and decentralise the healthcare industry with a global opportunity of overUS$1.3 trillion. * Prenetics' multi-product healthcare ecosystem strategy is driven by prevention focused genomic testing, rapid diagnostics for COVID-19 and infectious diseases, and c...
2021-09-16 06:00
7815
New Therapy to Treat Advanced Small Cell Lung Cancer Approved for Australian Patients
Highlights: * ZEPZELCA® (lurbinectedin) is the first new therapy approved to treat second-line metastatic SCLC inAustralia in more than 20 years * * ZEPZELCA approval granted under a provisional regulatory pathway * US FDA and TGA collaborated via 'Project Orbis' to accelerate avail...
2021-09-14 18:57
592
Week's Top Stories
Most Reposted
Xinhua Silk Road: Annual report on image of Suzhou city released to better tell Suzhou stories during 2021 AI Expo Thu.
[Picked up by 157 media titles]
2021-09-18 16:13
TerraPay partners with MOVii to pave the way for seamless cross-border payments for Colombian residents and diaspora across the world
[Picked up by 150 media titles]
2021-09-21 09:00India to Host World's Largest Virtual FinTech Fest on 28th-30th Sept
[Picked up by 146 media titles]
2021-09-21 03:53
PouchNATION raises a Bridge Funding Round as Markets are preparing to reopen and launches Contactless Hospitality Tech
[Picked up by 145 media titles]
2021-09-23 10:12
Innovent Releases Interim Analysis Results of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma in the Phase 3 ORIENT-15 Study at ESMO Congress 2021
[Picked up by 137 media titles]
2021-09-18 08:00Most Read
Lufax Joins FTSE ESG Low Carbon Select Indexes
2021-09-18 10:00
20050
MINISO Group Files Annual Report on Form 20-F for Fiscal Year 2021
2021-09-17 20:45
16326
RYB Education, Inc. Reports Second Quarter 2021 Financial Results
2021-09-17 20:00
16202
RYB Education, Inc. Announces Change of Board Composition
2021-09-17 20:00
16073